Αρχική World News FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer World News FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer Από Ogkologos - 16 Σεπτεμβρίου, 2026 115 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARROS-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Self-care Isn’t Selfish 25 Αυγούστου, 2021 TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in... 12 Δεκεμβρίου, 2020 Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases 20 Ιουνίου, 2023 Gilteritinib Improves Survival in AML with FLT3 Mutations 27 Νοεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Mom Discovers She Has Breast Cancer After Weaning Twin Boys, Says... Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects